Ontology highlight
ABSTRACT:
SUBMITTER: Shen Y
PROVIDER: S-EPMC7750800 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Asian journal of pharmaceutical sciences 20200305 6
Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAAs) is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targets for ADCs. In addition, intracellular somatic mutant proteins can be presented on the cell surface by human leukocyte antigen class I (HLA I)molecules forming tumor-specific peptide/HLA I complexes. KRAS G12V mutation frequently occurred in varied ...[more]